Galera Therapeutics Inc

NASDAQ:GRTX   4:00:00 PM EDT
1.65
+0.01 (+0.61%)
Earnings Announcements

Galera Reports Third Quarter 2022 Financial Results

Published: 11/09/2022 12:30 GMT
Galera Therapeutics Inc (GRTX) - Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates.
Galera Therapeutics Inc Q3 Loss per Share $0.60.
On Track to Submit NDA to U.S. FDA for Avasopasem by End of 2022.
As of September 30, 2022, Co Had Cash, Cash Equivalents and Short-term Investments of $42.8 Million.
Co Expects Existing Cash, Cash Equivalents & Short-term Investments Will Enable Co to Fund Operating Expenses & Capex Requirements Into H2 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.52

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.